DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Friday, 20 May 2016

Alisa Hagen


Alisa Hagen
M.Sc. Student.
Institute of Chemistry and the Center for Nanoscience and Nanotechnology
Jerusalem, 91904.
Israel.
Email: alisa.hagen@mail.huji.ac.il
Tel.: +972-2-6586985
FAX: +972-2-6584148
https://il.linkedin.com/in/alisa-hagen-9b142192
https://www.facebook.com/alisa.hagen


The Banin Group
/////
Posted by at 1 comment:
Labels:

Thursday, 19 May 2016

Liron Oskar

Liron Oskar


Liron Oskar

Research and Development Chemist at Taro Pharmaceutical Industries

links


Experience




Research and Development Organic Chemist

Taro Pharmaceutical Industries
 – Present (1 year 5 months)Haifa, Israel



Laboratory Teaching Assistant

Technion - Israel Institute of Technology
 –  (1 year 11 months)

Education



Technion - Israel Institute of Technology

Bachelor's degree, Chemistry

.

 





M.Sc Thesis

M.Sc StudentLiron Oskar
SubjectMerging Allylic Carbon-Hydrogen and Carbon-Carbon Bond
Activations en-route to Sophisticated
Molecular Framework
DepartmentDepartment of Chemistry
SupervisorFull Professors Marek Ilan
Full Thesis textFull thesis text - English Version
http://www.graduate.technion.ac.il/Theses/Abstracts.asp?Id=29080

Abstract

Recently, our group has developed the zirconocene-mediated ring opening of alkylidenecyclopropanes (ACPs) and w-ene cyclopropanes derivatives, via a unique and selective merging of allylic carbon-hydrogen and carbon-carbon bond activations, leading to bismetallated zirconocene complex. The addition of two different electrophiles gives bisfunctionalized acyclic molecules in excellent yields. By diversifying the nature of the two electrophiles, two stereogenic centers were created with high diastereoselectivity.
In this context, we proposed to enlarge the scope of this process by creating three stereogenic centers in an acyclic product via a one-pot sequence, while studying the diastereoselectivity.
Since zirconocene-mediated ring opening was done with stoichiometric amount of zirconocene complex, we tried to develop a catalytic process for the ring cleavage applied on ACPs derivatives, based on the successful catalytic carbozirconation on multiple bonds.
A deeper mechanistic understanding of the combined allylic carbon-hydrogen and carbon-carbon bond activations pathway was also proposed, using labeled experiments.
Finally, we applied our zirconocene-mediated ring opening methodology to the synthesis of the two enantiomers of deuterated neopentane: the smallest enantiomerically enriched hydrocarbons that possess an all-carbon quaternary stereocenter, that is, a carbon center with four different non-hydrogen substituents. Using advanced and sensitive methods, we successfully determined their absolute configuration.





http://indianexpress.com/article/business/business-others/sun-pharma-shares-at-record-high-hopes-of-higher-sales-in-key-cancer-drug/


///////
Posted by at No comments:
Labels:

Jigisha Varia

Jigisha Varia RAC (US).


Jigisha Varia RAC (US)

Associate Director Regulatory Affairs at eVenus Pharmaceutical Laboratories, Inc.


 links

 https://www.linkedin.com/in/jigisha-varia-rac-us-09636014





xperience



Associate Director Regulatory Affairs

eVenus Pharmaceutical Laboratories Inc.
– Present (4 months)Greater New York City Area


Senior Manager Regulatory Affairs

eVenus Pharmaceutical Laboratories, Inc.
– (9 months)Greater New York City Area


Manager Regulatory Affairs

SUN PHARMA
– (1 year 10 months)Greater New York City Area


Senior Associate, Regulatory affairs

SUN PHARMA
– (2 years 1 month)greater detroit area


Senior Regulatory affairs/Product development

Revogenex Inc
– (2 years 5 months)


Senior Research scientist

Alembic
– (4 years 2 months)


Research associate

SUN PHARMA
– (7 months)



Education


The Maharaja Sayajirao University of Baroda

Maters in pharmaceutical technology, pharmaceutics


/////////
Posted by at No comments:
Labels:

Renana Poranne

Renana Poranne

Renana Poranne

PostDoc Researcher - ETH Zurich
links
https://ch.linkedin.com/in/renana-poranne-b687a3ba
https://www.researchgate.net/profile/Renana_Gershoni-Poranne
 https://www.facebook.com/renana.poranne
  • ETH Zurich
    Department of Chemistry and Applied Biosciences
    Zürich, ZH, Switzerland

Experience

Postdoctoral Researcher

ETH Zurich
– Present (9 months)Zürich Area, Switzerland

Education

Technion - Israel Institute of Technology

Bachelor of Science (BSc), Molecular Biochemistry, 96.6

Activities and Societies: Student Body Representative
Technion PhD student Renana Gershoni Poranne soaks in the magic of Mainau Island on a lunch break from scientific mingling

Research experience

 
  • Sep 2015–present
     
    PostDoc Position
    ETH Zurich · Department of Chemistry and Applied Biosciences · Chen
    Switzerland · Zürich, Zurich
  • Apr 2010–Jul 2015
     
    PhD Student
    Technion - Israel Institute of Technology · Schulich Faculty of Chemistry · Stanger
    Israel · Haifa
  • Sep 2007–Apr 2010
     
    Master's Student
    Technion - Israel Institute of Technology · Faculty of Chemistry · Keinan
    Israel · Haifa, Haifa
     
     
     
     
     
     
     


/////Renana Poranne
Posted by at No comments:
Labels:

Wednesday, 18 May 2016

Ayomi S. Perera



Ayomi S. Perera




Alternate, sustainable energy sources are gaining increased attention from chemists, physicists and engineers, as mankind realizes the limited availability and adverse environmental impacts of burning fossil fuels. Solar cells have great potential to be used as a sustainable and green energy source for the future. In this regard a prototype of a nano solar cell containing the Mycobacterial channel protein MspA, as the matrix for vectorial electron transport has been successfully achieved.
MspA is an octameric trans-membrane channel protein (i.e. porin) produced by Mycobacterium smegmatis and is one of the most stable porins known so far. Wild type MspA has been successfully isolated, analyzed and purified to obtain crystals. A novel Ruthenium-phenanthroline-viologen-maleimide dye which is a fast vectorial electron transporter, has been synthesized, purified and successfully bound to the terminal end of wild type MspA, via the cysteine-maleimide bond. The dye-protein complex has then been adsorbed onto TiO2 plates and subjected to incident sunlight. The protein appeared to be stable under the incident wavelength and a steady current is observed. A 1% incident photon conversion efficiency of sunlight into current by the MspA-dye complex has been achieved so far. This finding marks the first ever evidence of a ‘protein nano solar cell’. Future developments to enhance the efficiency of the system are proposed.
View Poster


https://www.researchgate.net/profile/Ayomi_Perera2/publications

Design of a Mycobacterial Porin Based Dye Sensitized Solar Cell - GRAND PRIZE WINNER - Ayomi S. Perera, Navaneetha K. Subbaiyan, Mausam Kalita, Sebastian Wendel, Francis D'Souza - Stefan H. Bossmann - Kansas










Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)